R

REMUS PHARMACEUTICALS L

REMUSNSE
Market snapshot · 2026-08-10 21:12 UTC

834.75

₹-7.50 (-0.89%)

MARKET CAP

STOCK P/E

52W HIGH

₹862.95

52W LOW

₹825.00

BOOK VALUE

EPS

ROE

SECTOR

Healthcare

DEBT/EQUITY

VOLUME

14,800

P/B RATIO

PEG RATIO

Sector

Healthcare

Themes

Pharmaceuticals
₹835.75₹835.50₹835.25₹835.00₹834.75VolumeAug '26

AI Summary

✦ Clartha

Valuation Metrics

Forward Valuation Outlook

Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.

Historical valuation metrics are unavailable for this ticker right now.

Peers & Comparison

Sector: Healthcare · Theme: Pharmaceuticals

Pharmaceuticals Peers2 peers
Avg P/E: 43.8x
CompanyRev. GrowthMarginP/Evs Avg52W Perf.
AKUMS DRUGS AND PHARMA L
AKUMSPharmaceuticals
+9.6%5.9%
43.8x
Fair
0% vs avg
+45.4%
BLUE JET HEALTHCARE LTD
BLUEJETPharmaceuticals
-17.4%26.5%
43.7x
Fair
0% vs avg
-25.8%
WHY THESE PEERS

REMUS.NS,0P0001R0B2,5700 trades in line with peers (48.8x vs avg 43.8x), reflecting a fair valuation within the Pharmaceuticals cohort. Peers include AKUMS DRUGS AND PHARMA L, BLUE JET HEALTHCARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.

Financials

Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.

Latest revenue

₹453 CrMar 2026

Latest net profit

₹19 CrMar 2026

Latest EPS

₹20.86Mar 2026

Net margin

6.2%Mar 2026

Performance

Bars show revenue and net profit. The line shows net margin.

Rs crore + margin %
Q4 '25Q1 '26Q2 '26Q3 '26Q4 '260.0%2.0%4.0%6.0%8.0%0.00 Cr150 Cr300 Cr450 Cr600 Cr
  • Revenue
  • Net income
  • Net margin %

Earnings

Revenue is shown in crores. EPS is rupees per share.

Rs crore + Rs/share
Q4 '25Q1 '26Q2 '26Q3 '26Q4 '260.00 Cr150 Cr300 Cr450 Cr600 Cr₹0₹6₹12₹18₹24
  • Revenue
  • EPS

Revenue to profit conversion

Bridge from operating numbers to profit for the latest reported period.

Rs crore
RevenueExpensesDepreciationOtheradjustmentsOperatingprofitOther incomeInterestProfitbefore taxTax & otherNet Profit0.00 Cr150 Cr300 Cr450 Cr600 Cr

Latest reported period: Mar 2026

Debt level and coverage

Debt, cash and free cash flow compared on the same crore scale.

Rs crore
Annual view
Sep 2025Mar 20260.00 Cr150 Cr300 Cr450 Cr600 Cr
  • Debt
  • Free cash flow
  • Cash & equivalents

Results

Sales

₹453 Cr

Net Profit

₹19 Cr

EBITDA

₹34 Cr

EPS

₹20.86

MetricMar 2025Mar 2026
Sales348453
Expenses324425
Operating Profit2328
OPM %6.72%6.24%
Other Income34
Interest11
Depreciation11
Profit before tax2531
Tax %18.86%21.37%
Net Profit1619
EPS in Rs17.4620.86

All values in ₹ Crores unless otherwise stated. Source: Company filings.

Shareholding Pattern

HolderSep 2024Oct 2024Mar 2025Sep 2025Mar 2026
Promoters70.84%70.66%70.85%70.91%70.95%
FII3.16%3.00%4.77%5.02%5.28%
DII0.77%0.73%0.77%0.77%0.83%
Public20.48%20.90%19.18%18.78%18.50%
Others4.75%4.71%4.43%4.52%4.44%
Mar 2026
Promoters
FII
DII
Public
Others